Breakthrough Treatment of Hypertension, Hypertension’s “Syndrome X” is now Re-defined.
نویسندگان
چکیده
منابع مشابه
Defined Radios - The Future is Now
A Software Defined Radio (SDR) is a radio in which all modulation and demodulation functions are defined, and therefore configurable, through software. This creates tremendous flexibility to improve and adapt the capabilities of the radio over time without changing the hardware. The potential for amateur radio experimentation is virtually limitless in terms of performance improvement and the in...
متن کاملThe Software-defined Radio Is Now a Reality
The role of firmware and digital signal processing in radio transceiver design has increased to meet the global coverage requirement and to cover extra features in the mobile telephony. The Software-Defined Radio (SDR) is the practical approach for this. The paper reviews the SDR concepts, the benefits, the design steps involved in SDR, some emerging concepts, technological solutions and challe...
متن کاملCompliance and the treatment of hypertension: where are we now?
Hypertension is a major risk factor for cardiovascular disease, and is associated with significant target-organ damage, such as left ventricular hypertrophy, renal disease, ischemic heart disease and cerebrovascular disease [1]. The treatment (and control) of hypertension reduces cardiovascular risk and delays (or reverses) target-organ damage, where present. It is therefore of utmost importanc...
متن کاملAmines in experimental hypertensions.
A sympathomimetic timine, Paredrine, was shown to be a good antihypertensive agent in experimental renal, experimental neurogenic and spontaneous hypertensions in the dog. Other closely related amines failed to possess antihypertensive activity. Paredrine did not prevent the development of experimental renal hypertension. This amine was also without chronic effect on the blood pressure of normo...
متن کاملIs natalizumab a breakthrough in the treatment of multiple sclerosis?
In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: IOSR Journal of Dental and Medical Sciences
سال: 2012
ISSN: 2279-0861,2279-0853
DOI: 10.9790/0853-0153338